Today, Zacks Investment Ideas feature highlights Gilead Sciences GILD and Johnson & Johnson JNJ. Buy Gilead Sciences (GILD ...

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

We recently published a list of Top 10 Stocks Wall Street is Discussing. In this article, we are going to take a look at ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price upped by Wells Fargo & Company from $120.00 to $140.00 ...